Company profile

Future of Zeltiq Aesthetics

#
Rank
852
| Quantumrun Global 1000

The ZELTIQ Aesthetics is a public sector corporation. It is based in Pleasanton, California. This organization aims to market and license the procedure of CoolSculpting cryolipolysis. The ZELTIQ Aesthetics company has the largest share of market for all non-invasive fat decreasing practices. Its one and only product is CoolSCulpting, which is "the main Cryolipolysis device available in the market." This company was built in 2005 and has raised over 75 million dollars in funding processes before going out to the public in the year 2011. Its CoolSculpting modus operandi was given approval by the Food and Drug Administration for the "body-sculpting" procedure on the sides or flanks in 2010, along with thighs in 2014, and stomach fat in 2012.

Home Country:
Sector:
Industry:
Cryolipolysis
Founded:
2005
Global employee count:
500
Domestic employee count:
Number of domestic locations:
4

Financial Health

Revenue:
$354201000 USD
3y average revenue:
$261365000 USD
Operating expenses:
$237450000 USD
3y average expenses:
$179029000 USD
Funds in reserve:
$54815000 USD
Market country
Revenue from country
0.75

Asset Performance

  1. Product/Service/Dept. name
    System revenue
    Product/Service revenue
    130698000
  2. Product/Service/Dept. name
    Consumable revenue
    Product/Service revenue
    124718000

Innovation assets and Pipeline

Investment into R&D:
$25522000 USD
Total patents held:
16

All company data collected from its 2016 annual report and other public sources. The accuracy of this data and the conclusions derived from them depend on this publicly accessible data. If a data point listed above is discovered to be inaccurate, Quantumrun will make the necessary corrections to this live page. 

DISRUPTION VULNERABILITY

Belonging to the healthcare sector means this company will be affected directly and indirectly by a number of disruptive opportunities and challenges over the coming decades. While described in detail within Quantumrun’s special reports, these disruptive trends can be summarized along the following broad points:

*First off, the late 2020s will see the Silent and Boomer generations enter deep into their senior years. Representing nearly 30-40 per cent of the global population, this combined demographic will represent a significant strain on the health systems of developed nations. *However, as an engaged and wealthy voting block, this demographic will actively vote for increased public spending on subsidized health services (hospitals, emergency care, nursing homes, etc.) to support them in their greying years.

*The economic strain caused this massive senior citizen demographic will encourage developed nations to fast-track the testing and approval process for new drugs, surgeries and treatment protocols that may improve the overall physical and mental health of patients to a point where they can lead independent lives outside of the health care system.

*This increased investment into the health care system will include a greater emphasis on preventative medicine and treatments.

*By the early 2030s, the most profound preventative health care treatment will become available: treatments to stunt and later reverse the effects of aging. These treatments will be provided annually and, over time, will become affordable to the masses. This health revolution will result in a reduced usage and strain on the overall health care system—since younger people/bodies use less health care resources, on average, than people in older, sicker bodies.

*Increasingly, we will use artificial intelligence systems diagnose patients and robots to manage intricate surgeries.

*By the late 2030s, technological implants will correct any physical injury, while brain implants and memory erasure drugs will cure most any mental trauma or illness.

*By the mid-2030s, all medicines will be customized to your unique genome and microbiome.

COMPANY’S FUTURE PROSPECTS

Company Headlines